Cargando…
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
BACKGROUND: Multiple farnesylated proteins are involved in signal transduction in cancer. Farnesyltransferase inhibitors (FTIs) have been developed as a strategy to inhibit the function of these proteins. As FTIs inhibit proliferation of melanoma cell lines, we undertook a study to assess the impact...
Autores principales: | Gajewski, Thomas F, Salama, April KS, Niedzwiecki, Donna, Johnson, Jeffrey, Linette, Gerald, Bucher, Cynthia, Blaskovich, Michelle A, Sebti, Said M, Haluska, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543225/ https://www.ncbi.nlm.nih.gov/pubmed/23228035 http://dx.doi.org/10.1186/1479-5876-10-246 |
Ejemplares similares
-
Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum
por: Ha, Young Ran, et al.
Publicado: (2015) -
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005) -
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance)
por: Fuchs, Michael A., et al.
Publicado: (2014) -
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance)
por: Lee, Seohyuk, et al.
Publicado: (2021) -
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)
por: Brown, Justin C, et al.
Publicado: (2019)